DGM
STOK icon

Darwin Global Management’s Stoke Therapeutics STOK Stock Holding History

Darwin Global Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,000
Closed -$372K – 14
2020
Q4 		$372K Buy
+6,000
New +$275K 0.1% 12

Other funds holding STOK

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Darwin Global Management's STOK Position: Q1 2021 in Review

Darwin Global Management sold out of Stoke Therapeutics (STOK) in Q1 2021, closing a stake of 6,000 shares — an estimated $372K sold.

Darwin Global Management first reported a position in STOK in Q4 2020 and held it in 1 quarter. The position peaked at $372K in Q4 2020. 106 funds tracked by Wall St. Rank hold STOK as of Q1 2021.

  • Darwin Global Management reported no remaining Stoke Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Darwin Global Management sold 6,000 Stoke Therapeutics shares in Q1 2021, an estimated $372K.
  • Darwin Global Management first reported a position in Stoke Therapeutics in Q4 2020 and held it in 1 quarter.
  • Darwin Global Management's Stoke Therapeutics position peaked at $372K in Q4 2020.
  • 106 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2021.

Based on Darwin Global Management's 13F filing for Q1 2021, filed 17 May 2021.